[Skip to Content]
[Skip to Content Landing]
December 7, 1957


JAMA. 1957;165(14):1860. doi:10.1001/jama.1957.02980320090021

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  Due to the shortage of the current Asian strain influenza vaccine, much interest has been raised as to the possibility of immunizing persons with 0.1 ml. of the vaccine injected intradermally rather than with the presently recommended dose of 1.0 ml. of the vaccine given subcutaneously. This thought has been raised by the intradermal use of other types of vaccine (J.A.M.A.164:1626 [Aug. 3] 1957) showing the development of antibodies but without the necessary proof of actual human protection in an epidemic. In the Correspondence section of The Journal ( 165:278 [Sept. 21] 1957), Dr. Louis Tuft implied that the intradermal injection of 0.1 ml. of influenza vaccine will confer protection against the disease. The basis for his recommendation is the production of antibodies as measured by the hemagglutination inhibition (HI) test after intradermal inoculation of the vaccine.The production of HI antibodies does not necessarily

First Page Preview View Large
First page PDF preview
First page PDF preview